Reply to: "QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights".

Hummel, James P; Akar, Joseph G

Hummel, James P; Akar, Joseph G.

Hummel JP; Department of Internal Medicine, Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Akar JG; Department of Internal Medicine, Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

J Cardiovasc Electrophysiol ; 31(10): 2795, 2020 10.

Article in English | MEDLINE | ID: covidwho-735929

Subject(s)

Arrhythmias, Cardiac; Azithromycin; COVID-19; Arrhythmias, Cardiac/etiology; Azithromycin/adverse effects; Humans; Hydroxychloroquine/adverse effects; Pandemics; Pharmacogenetics; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Arrhythmias, Cardiac / Azithromycin / COVID-19 Limits: Humans Language: English Journal: J Cardiovasc Electrophysiol Journal subject: Vascular Diseases / Cardiology / Physiology Year: 2020 Document Type: Article Affiliation country: Jce.14721

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google